IBM to sell part of its Watson Health business, including image software offerings and extensive data sets, to PE firm Francisco Partners, sources say for $1B+
International Business Machines Corp. agreed to sell part of its IBM Watson Health business to private equity firm Francisco Partners …
Context & Ripple Effects
Watson Health was assembled by acquisition — IBM paid $1B for Merge Healthcare in 2015 to add medical images and $2.6B for Truven Health Analytics in 2016, roughly $4B of M&A in total for a division with about $1B in revenue that never turned profitable. After first exploring a sale in early 2021 and restarting the process earlier this month, IBM has now agreed to hand part of the unit — the imaging software and its extensive data sets — to Francisco Partners for a reported $1B-plus.
The buyer is no stranger to this playbook: Francisco Partners is the same firm that would go on to take IBM's weather business, including Weather.com, off its hands, and it has been carving out corporate units like Moneris from Royal Bank of Canada and Bank of Montreal. Big Tech's healthcare moonshots are being recycled into PE-owned specialists.
First-order effects
- Francisco Partners acquires medical-imaging software and large health data sets for a reported $1B+ — a fraction of the ~$4B IBM spent building Watson Health through the Merge Healthcare and Truven Health Analytics deals.
Second-order effects
- IBM exits an unprofitable, non-core line and sharpens its portfolio around cloud and AI infrastructure, while Francisco Partners extends a run of corporate carve-outs (IBM's weather business, Moneris, Weave Communications) that positions it as the default buyer for conglomerate divestitures.
Third-order effects
- If the pattern holds, flagship tech-company bets on healthcare AI keep getting unbundled: integrated divisions built during the AI-hype cycle are split apart, with data sets and vertical software moving to financial buyers who can run them leaner than their original owners could.
The trend: Enterprise AI is being unbundled — conglomerates like IBM are shedding hyped vertical-AI divisions to private equity specialists rather than fixing them in-house.